AURKA and lung carcinoma: In another study, the combined treatment with valproic acid (VPA), belonging to histone deacetylase inhibitors and the Ras inhibitor, farnesylthiosalicylic acid (FTS), salirasib synergistically reduced the proliferation of A549 lung cancer cells, DLD1 colon, and ARO thyroid carcinoma cells by downregulating Ras and blocking the expression of survivin and AURKA [55].